



Critech Will Attend BioPartnering Europe, Vienna

October 27, 2009

For Immediate Release

LAWRENCE - Kansas-based Critech Inc. is pleased to announce their participation at BioPartnering Europe.

The purpose of the meeting is to bring innovative and emerging companies in the Life Science Industries together with key members of the pharmaceutical, venture capital, and finance industries for partnering and collaboration.

The meeting will be held on November 2-4 2009 in Vienna Austria.

Critech's CEO David Johnston will be presenting in the cancer section of the meeting and will be highlighting the company's Nanotax™ product which has been enabled by the company's proprietary technology. Critech is currently accepting appointments for meetings at this event. If your schedules at BioPartnering do not allow our groups to meet or if you are not attending BioPartnering we are also available to meet outside of the conference schedule so please contact us if you want to schedule a meeting.

For further information please contact:

David Johnston, PhD., CEO

Sam Campbell, President

Joe Fix, VP of Business Development

Critech, Inc
1321 Wakarusa Drive
Suite 2102
Lawrence
KS 66049
Tel: 785 841 7120
Fax: 785 841 7268

Critech, Inc. conducts research and development into the production and application of fine-particle compounds including fine particle API production. Internal product development is focused on a portfolio of products for the treatment of cancers. The company has expanded the application of the technology to include coatings of pharmaceutical products and devices, and the non-aqueous precipitation of proteins. These technology solutions can also be applied to external programs and product life cycle management.